Rheumatoid arthritis - Early diagnosis and disease management;Rheumatoide arthritis - Frühdiagnose und krankheitskontrolle

Deutsches Arzteblatt International

Volumn 110, Issue 27-28, 2013, Pages 477-484

  Schneider, Matthias ^a   Krüger, Klaus ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Praxiszentrum St Bonifatius   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CORTISONE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ACUTE PHASE RESPONSE; ARTHRALGIA; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; DYNAMIC EXERCISE; EARLY DIAGNOSIS; EARLY INTERVENTION; ENDURANCE TRAINING; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL DISEASE; HUMAN; JOINT EXAMINATION; JOINT SWELLING; META ANALYSIS (TOPIC); MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PHYSICAL DISABILITY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGNOSIS; PROGNOSTIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SEROLOGY; SYSTEMATIC REVIEW;

EID: 84906329070     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2013.0477     Document Type: Review

References (40)

1. Westhoff G, Schneider M, Raspe H, et al.: Advance and unmet need of health care for patients with rheumatoid arthritis in the German population-results from the German Rheumatoid Arthritis Population Survey (GRAPS). Rheumatology 2009; 48: 650-7.
2. Scott DL, Coulton BL, Symmons DPM, Popert AJ: Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987: 1108-11.
3. Pincus T, Callahan LF, Sale WG, et al.: Severe functional decline, work disability, and increased mortality in 75 rheumatoid arthritis patients studied over 9 years. Arthritis Rheum 1984; 27: 864-72.
4. Schneider M, Lelgemann M, Abholz HH, et al.: Management der frühen rheumatoiden Arthritis. Heidelberg: Springer Verlag 2011. http://dgrh.de/leitlinien.html
5. Albrecht K, Krüger K, Müller-Ladner U, Wollenhaupt J: Systematische Literaturrecherche für die S1-Leitlinie der DGRh zur sequenziellen medikamentösen Therapie der rheumatoiden Arthritis 2011. Z Rheumatol 2012; 71: 604-18.
6. Aletaha D, Neogi T, Silman AJ, et al.: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69: 1580-8.
7. Neogi T, Aletaha D, Silman AJ, et al.: American College of Rheumatology; European League Against Rheumatism. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum 2010; 62: 2582-91.
8. Niedermann K, Fransen J, Knols R, Uebelhart D: Gap between short- and long-term effects of patient education in rheumatoid arthritis patients: a systematic review. Arthritis Rheum 2004; 51: 388-98.
9. Steultjens EM, Dekker J, Bouter LM, et al.: Occupational therapy for rheumatoid arthritis. Cochrane Database Syst Rev 2004; (1): CD003114.
10. van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC: The severity of rheumatoid arthritis: a 6-year followup study of younger women with symptoms of recent onset. J Rheumatol 1994; 21: 1620-5.
11. Wiles NJ, Lunt M, Barrett EM, et al.: Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum 2001; 44: 1033-42.
12. Lindqvist E, Saxne T, Geborek P, Eberhardt K: Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 2002; 61: 1055-9.
13. Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, et al.: The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the Best study. Ann Rheum Dis 2011; 70: 1039-46.
14. Mottonen T, Hannonen P, Korpela M, et al.: Delay to institution of therapy and induction of remission using single-drug or combination disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 894-8.
15. Jansen LM, van der Horst-Bruinsma IE, van SD, Bezemer PD, Dijkmans BA: Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 2001; 60: 924-7.
16. Jones G, Halbert J, Crotty M, et al.: The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology (Oxford) 2003; 42: 6-13.
17. Bukhari MA, Wiles NJ, Lunt M, et al.: Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: Results from a large observational inception study. Arthritis Rheum 2003; 48: 46-53.
18. Egsmose C, Lund B, Borg G, et al.: Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995; 22: 2208-13.
19. Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al.: Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 2000; 27: 623-9.
20. Wevers-de Boer K, Visser K, Heimanns L, et al.: Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis 2012; 71: 1472-7.
21. van Aken J, Lard LR, Le Cessie S, et al.: Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004; 63: 274-9.
22. van der Linden MPM, Le Cessie S, Raza K, et al.: Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 2010; 62: 3537-46.
23. Choi HK, Hernan MA, Seeger JD, et al.: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
24. Peltomaa R, Paimela L, Kautiainen H, Leirisalo-Repo M: Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Ann Rheum Dis 2002; 61: 889-94.
25. van Nies JAB, de Jong Z, van der Helm-van Mil AHM, et al.: Improved treatment strategies reduce the increased mortality risk in early arthritis patients. Rheumatology 2010; 49: 2210-6.
26. Smolen JS, Aletaha D, Bijlsma JWJ, et al.: for the T2T Expert Committee: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
27. van Tuyl LHD, Felson DT, Wells G, Smolen J, Zhang B, Boers M, ACR & EULAR committee to define remission for clinical trials. Systematic review: Evidence for predictive validity of remission on long term outcome in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010; 62: 108-17.
28. Klarenbeek NB, Koevoets R, van der Heijde DM, et al.: Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis 2011, 70: 1815-21.
29. van den Broek M, Dirven L, de Vries-Bouwstra JK, et al.: Rapid radiological progression in the first year of early rheumatoid arthritis is predictive of disability and joint damage progression during 8 years of follow-up. Ann Rheum Dis 2012; 71: 1530-3.
30. Smolen JS, Han C, van der Heijde DMFM, et al.: Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2009; 68: 823-7.
31. Felson DT, Smolen JS, Wells G, et al.: American College of Rheumatology/European League Against Rheumatism: Provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011; 70: 404-13.
32. Soubrier M, Lukas C, Sibilia J, et al.: Disease activity scoredriven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 2011; 70: 611-5.
33. van Vollenhoven RF, Ernestam S, Geborek P, et al.: Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009, 374: 459-66.
34. Hetland ML, Stengaard-Pedersen K, Junker P, et al.: Combination treatment with Methotrexate, Cyclosporine, and intraarticular Betamethasone compared with Methotrexate and intraarticular Betamethasone in early active rheumatoid arthritis. Arthritis Rheum 2006; 54: 1401-9.
35. O'Dell JR, Leff R, Paulsen G: Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1164-70.
36. Kremer JM, Genovese MC, Cannon GW, et al.: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, doubleblind, placebo-controlled trial. Ann Intern Med 2002; 137: 726-33.
37. Smolen JS, Landewé R, Breedveld FC, et al.: EULAR recommendations for the management of rheumatoid arthritis with syn thetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
38. Emery P, Breedveld FC, Hall S, et al.: Comparison of metho - trexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-82.
39. Kavanaugh A, Fleischmann RM, Emery P, et al.: Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus metho - trexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013; 72: 64-71.
40. Krüger K, Wollenhaupt J, Albrecht K, et al.: S1-Leitlinie der DGRh zur sequenziellen medikamentösen Therapie der rheumatoiden Arthritis 2011: adaptierte EULAR Empfehlungen und aktualisierter Therapiealgorithmus. Z Rheumatol 2012; 71: 592-603.